Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV000056344 | SCV000087506 | pathogenic | Cystic fibrosis | 2017-03-17 | reviewed by expert panel | research | |
CFTR- |
RCV000056344 | SCV001169445 | pathogenic | Cystic fibrosis | 2018-01-29 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV000056344 | SCV002651686 | pathogenic | Cystic fibrosis | 2015-04-03 | criteria provided, single submitter | clinical testing | The p.W401* pathogenic mutation (also known as c.1203G>A), located in coding exon 9 of the CFTR gene, results from a G to A substitution at nucleotide position 1203. This changes the amino acid from a tryptophan to a stop codon within coding exon 9. This pathogenic mutation is associated with elevated sweat chloride levels, pancreatic insufficiency (PI), and decreased lung function (Sosnay PR et al. Nat Genet. 2013;45(10):1160-7, Supplementary Table and The Clinical and Functional Translation of CFTR (CFTR2); available at http://cftr2.org. Accessed April 2, 2015). In addition to the clinical data available in the literature, since premature stop codons are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Labcorp Genetics |
RCV000056344 | SCV003011447 | pathogenic | Cystic fibrosis | 2022-05-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 53213). This premature translational stop signal has been observed in individual(s) with cystic fibrosis (PMID: 7508414, 23974870). This variant is present in population databases (rs397508175, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Trp401*) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). |
Natera, |
RCV001831721 | SCV002080556 | pathogenic | CFTR-related disorder | 2017-03-17 | no assertion criteria provided | clinical testing |